Strategic Business Update Conference Call

March 14, 2023 – 8:30 AM ET

Latest Financial Results

FY 2022

Fiscal Year Ended Dec 31, 2022

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2022

Company Overview

Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device.

IR Contacts


Lucid Diagnostics Inc.
One Grand Central
60 East 42nd Street, Suite 4600
New York, NY 10165
T: 212-949-4319

Investor Relations

Michael Parks
Vice President of Investor Relations
M: 484-356-7105

Transfer Agent

Continental Stock Transfer & Trust Company
17 Battery Place
New York, NY 10004